{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:24:06Z","timestamp":1793129046244,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671818"],"award-info":[{"award-number":["81671818"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hubei Province health and family planning scientific research project, China","award":["WJ2019Z010"],"award-info":[{"award-number":["WJ2019Z010"]}]},{"name":"Science and Technology Program of Wuhan, China","award":["2017060201010148"],"award-info":[{"award-number":["2017060201010148"]}]},{"name":"Medical Science Advancement Program (Basic Medical Science) of Wuhan University, China","award":["TFJC20. 18003"],"award-info":[{"award-number":["TFJC20. 18003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Triple negative breast cancer (TNBC) has the poorest prognosis of all breast cancer subtypes and is one of the most fatal diseases for women. Combining cytotoxic chemotherapy with immunotherapy has shown great promise for TNBC treatment. However, chemotherapy often leads to the development of chemoresistance and severe systemic toxicity compromising the immune functions that are crucial to anti-TNBC immune therapy. Tumor-induced immunosuppression also poses a great hindrance to efficacious anti-TNBC immunotherapy. Nanomedicine holds great promise to overcome these hurdles.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Doxorubicin-polyglycerol-nanodiamond conjugate (Nano-DOX) was firstly found to be a cytostatic agent to the 4T1 cells and displayed a lower apparent therapeutic potency than DOX. However, the tumor-bearing animals, particularly some key immune cells thereof, showed good tolerance of Nano-DOX as opposed to the severe toxicity of DOX. Next, Nano-DOX did not induce significant upregulation of P-gp and IL-6, which were demonstrated to be key mediators of chemoresistance to DOX in the 4T1 cells. Then, Nano-DOX was shown to downregulate tumor-derived granulocyte-colony stimulating factor (G-CSF) and suppresses the induction and tissue filtration of myeloid-derived suppressor cells (MDSCs) that are the principal effectors of cancer-associated systemic immunosuppression. Nano-DOX also alleviated the phenotype of MDSCs induced by 4T1 cells. Finally, Nano-DOX induced the 4T1 cells to emit damage associated molecular patterns (DAMPs) that stimulated the tumor immune microenvironment through activating key immune effector cells involved in anti-tumor immunity, such as macrophages, dendritic cells and lymphocytes in the tumor tissue.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Nano-DOX is a cytostatic agent with good host tolerance which is capable of evading chemoresistance and reversing cancer-induced immunosuppression both at the systemic level and in the tumor microenvironment in TNBC. Our work presents Nano-DOX as an interesting example that a chemotherapeutic agent in nano-form may possess distinct biochemical properties from its free form, which can be exploited to join chemotherapy with immunotherapy for better treatment of cancer.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12951-019-0541-8","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T17:18:50Z","timestamp":1571332730000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer"],"prefix":"10.1186","volume":"17","author":[{"given":"Shen-Jun","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Hong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Chao","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Zhen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5474-0205","authenticated-orcid":false,"given":"Xiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,17]]},"reference":[{"key":"541_CR1","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","volume":"363","author":"WD Foulkes","year":"2010","unstructured":"Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938\u201348.","journal-title":"N Engl J Med"},{"key":"541_CR2","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1158\/0008-5472.CAN-07-5644","volume":"68","author":"M Smid","year":"2008","unstructured":"Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68:3108\u201314.","journal-title":"Cancer Res"},{"key":"541_CR3","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1002\/cncr.22618","volume":"109","author":"KR Bauer","year":"2007","unstructured":"Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109:1721\u20138.","journal-title":"Cancer"},{"key":"541_CR4","first-page":"106","volume":"12","author":"HA Wahba","year":"2015","unstructured":"Wahba HA, El-Hadaad HA. Current approaches in treatment of triple-negative breast cancer. Cancer Biol Med. 2015;12:106\u201316.","journal-title":"Cancer Biol Med."},{"key":"541_CR5","first-page":"52","volume":"7","author":"N McAndrew","year":"2018","unstructured":"McAndrew N, DeMichele A. Neoadjuvant chemotherapy considerations in triple-negative breast cancer. J Target Ther Cancer. 2018;7:52\u201369.","journal-title":"J Target Ther Cancer."},{"key":"541_CR6","doi-asserted-by":"publisher","first-page":"6823","DOI":"10.2147\/CMAR.S185176","volume":"10","author":"P Vikas","year":"2018","unstructured":"Vikas P, Borcherding N, Zhang W. The clinical promise of immunotherapy in triple-negative breast cancer. Cancer Manag Res. 2018;10:6823\u201333.","journal-title":"Cancer Manag Res."},{"key":"541_CR7","first-page":"137","volume":"33","author":"H McArthur","year":"2019","unstructured":"McArthur H. Combining chemotherapy and immunotherapy for the treatment of triple-negative breast cancer. Oncology (Williston Park). 2019;33:137\u201340.","journal-title":"Oncology (Williston Park)."},{"key":"541_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.canlet.2019.04.017","volume":"454","author":"Q Luo","year":"2019","unstructured":"Luo Q, Zhang L, Luo C, Jiang M. Emerging strategies in cancer therapy combining chemotherapy with immunotherapy. Cancer Lett. 2019;454:191\u2013203.","journal-title":"Cancer Lett"},{"key":"541_CR9","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/ncomms12150","volume":"7","author":"V Bronte","year":"2016","unstructured":"Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich DI. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016;7:12150.","journal-title":"Nat Commun."},{"key":"541_CR10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s12272-019-01150-z","volume":"42","author":"M Diederich","year":"2019","unstructured":"Diederich M. Natural compound inducers of immunogenic cell death. Arch Pharm Res. 2019;42:629\u201345.","journal-title":"Arch Pharm Res."},{"key":"541_CR11","doi-asserted-by":"publisher","first-page":"5393","DOI":"10.1016\/j.biomaterials.2014.03.041","volume":"35","author":"L Zhao","year":"2014","unstructured":"Zhao L, Xu YH, Akasaka T, Abe S, Komatsu N, Watari F, Chen X. Polyglycerol-coated nanodiamond as a macrophage-evading platform for selective drug delivery in cancer cells. Biomaterials. 2014;35:5393\u2013406.","journal-title":"Biomaterials"},{"key":"541_CR12","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jconrel.2017.10.024","volume":"268","author":"TF Li","year":"2017","unstructured":"Li TF, Li K, Wang C, Liu X, Wen Y, Xu YH, Zhang Q, Zhao QY, Shao M, Li YZ, Han M, Komatsu N, Zhao L, Chen X. Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nano-drug for modulation of glioblastoma immune microenvironment. J Control Release. 2017;268:128\u201346.","journal-title":"J Control Release"},{"key":"541_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.biomaterials.2018.07.035","volume":"181","author":"TF Li","year":"2018","unstructured":"Li TF, Li K, Zhang Q, Wang C, Yue Y, Chen Z, Yuan SJ, Liu X, Wen Y, Han M, Komatsu N, Xu YH, Zhao L, Chen X. Dendritic cell-mediated delivery of doxorubicin-polyglycerol-nanodiamond composites elicits enhanced anti-cancer immune response in glioblastoma. Biomaterials. 2018;181:35\u201352.","journal-title":"Biomaterials"},{"key":"541_CR14","doi-asserted-by":"publisher","first-page":"24506","DOI":"10.1038\/srep24506","volume":"6","author":"W He","year":"2016","unstructured":"He W, Liang P, Guo G, Huang Z, Niu Y, Dong L, Wang C, Zhang J. Re-polarizing Myeloid-derived Suppressor Cells (MDSCs) with cationic polymers for cancer immunotherapy. Sci Rep. 2016;6:24506.","journal-title":"Sci Rep."},{"key":"541_CR15","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1080\/15548627.2017.1386359","volume":"14","author":"SY Lin","year":"2018","unstructured":"Lin SY, Hsieh SY, Fan YT, Wei WC, Hsiao PW, Tsai DH, Wu TS, Yang NS. Necroptosis promotes autophagy-dependent upregulation of DAMP and results in immunosurveillance. Autophagy. 2018;14:778\u201395.","journal-title":"Autophagy."},{"key":"541_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2217\/nnm-2018-0330","volume":"14","author":"Z Chen","year":"2019","unstructured":"Chen Z, Wang C, Li TF, Li K, Yue Y, Liu X, Xu HZ, Wen Y, Zhang Q, Han M, Komatsu N, Xu YH, Zhao L, Chen X. Doxorubicin conjugated with nanodiamonds and in free form commit glioblastoma cells to heterodromous fates. Nanomedicine (Lond). 2019;14:335\u201351.","journal-title":"Nanomedicine (Lond)."},{"key":"541_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.yexmp.2006.06.007","volume":"82","author":"SA DuPre\u2019","year":"2007","unstructured":"DuPre\u2019 SA, Hunter KW Jr. Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: association with tumor-derived growth factors. Exp Mol Pathol. 2007;82:12\u201324.","journal-title":"Exp Mol Pathol"},{"key":"541_CR18","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1186\/1479-7364-3-3-281","volume":"3","author":"V Vasiliou","year":"2009","unstructured":"Vasiliou V, Vasiliou K, Nebert DW. Human ATP-binding cassette (ABC) transporter family. Hum Genomics. 2009;3:281\u201390.","journal-title":"Hum Genomics."},{"key":"541_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.nantod.2013.04.006","volume":"8","author":"P Ma","year":"2013","unstructured":"Ma P, Mumper RJ. Anthracycline Nano-delivery systems to overcome multiple drug resistance: a comprehensive review. Nano Today. 2013;8:313\u201331.","journal-title":"Nano Today."},{"key":"541_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15:234\u201348.","journal-title":"Nat Rev Clin Oncol."},{"key":"541_CR21","first-page":"8851","volume":"61","author":"D Conze","year":"2001","unstructured":"Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P, Rinc\u00f3n M. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res. 2001;61:8851\u20138.","journal-title":"Cancer Res"},{"key":"541_CR22","doi-asserted-by":"publisher","first-page":"e22039","DOI":"10.1002\/jbt.22039","volume":"32","author":"K Wang","year":"2018","unstructured":"Wang K, Zhu X, Zhang K, Yin Y, Chen Y, Zhang T. Interleukin-6 contributes to chemoresistance in MDA-MB-231 cells via targeting HIF-1\u03b1. J Biochem Mol Toxicol. 2018;32:e22039.","journal-title":"J Biochem Mol Toxicol"},{"key":"541_CR23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3389\/fonc.2019.00295","volume":"9","author":"M Tavakkoli","year":"2019","unstructured":"Tavakkoli M, Wilkins CR, Mones JV, Mauro MJ. A novel paradigm between leukocytosis, G-CSF secretion, neutrophil-to-lymphocyte ratio, myeloid-derived suppressor cells, and prognosis in non-small cell lung cancer. Front Oncol. 2019;9:295.","journal-title":"Front Oncol."},{"key":"541_CR24","first-page":"11","volume":"24","author":"L Bravo","year":"1996","unstructured":"Bravo L, Legendre AM, Hahn KA, Rohrbach BW, Abraha T, Lothrop CD Jr. Serum granulocyte colony-stimulating factor (G-CSF) and interleukin-1 (IL-1) concentrations after chemotherapy-induced neutropenia in normal and tumor-bearing dogs. Exp Hematol. 1996;24:11\u20137.","journal-title":"Exp Hematol"},{"key":"541_CR25","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/oxfordjournals.jjco.a023173","volume":"26","author":"YM Chen","year":"1996","unstructured":"Chen YM, Whang-Peng J, Liu JM, Kuo BI, Wang SY, Tsai CM, Perng RP. Serum cytokine level fluctuations in chemotherapy-induced myelosuppression. Jpn J Clin Oncol. 1996;26:18\u201323.","journal-title":"Jpn J Clin Oncol"},{"key":"541_CR26","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/2326-6066.CIR-17-0502","volume":"6","author":"N Siriwon","year":"2018","unstructured":"Siriwon N, Kim YJ, Siegler E, Chen X, Rohrs JA, Liu Y, Wang P. CAR-T cells surface-engineered with drug-encapsulated nanoparticles can ameliorate intratumoral T-cell hypofunction. Cancer Immunol Res. 2018;6:812\u201324.","journal-title":"Cancer Immunol Res"},{"key":"541_CR27","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.actbio.2019.01.020","volume":"86","author":"TF Li","year":"2019","unstructured":"Li TF, Xu YH, Li K, Wang C, Liu X, Yue Y, Chen Z, Yuan SJ, Wen Y, Zhang Q, Han M, Komatsu N, Zhao L, Chen X. Doxorubicin-polyglycerol-nanodiamond composites stimulate glioblastoma cell immunogenicity through activation of autophagy. Acta Biomater. 2019;86:381\u201394.","journal-title":"Acta Biomater"},{"key":"541_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2217\/nnm-2017-0266","volume":"13","author":"C Wang","year":"2018","unstructured":"Wang C, Li K, Li T, Chen Z, Wen Y, Liu X, Jia X, Zhang Y, Xu Y, Han M, Komatsu N, Zhao L, Chen X. Monocyte-mediated chemotherapy drug delivery in glioblastoma. Nanomedicine (Lond). 2018;13:157\u201378.","journal-title":"Nanomedicine (Lond)."},{"key":"541_CR29","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/1440-1681.12581","volume":"43","author":"ST Pan","year":"2016","unstructured":"Pan ST, Li ZL, He ZX, Qiu JX, Zhou SF. Molecular mechanisms for tumour resistance to chemotherapy. Clin Exp Pharmacol Physiol. 2016;43:723\u201337.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"541_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.drup.2017.10.003","volume":"32","author":"I Genovese","year":"2017","unstructured":"Genovese I, Ilari A, Assaraf YG, Fazi F, Colotti G. Not only P-glycoprotein: amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. Drug Resist Update. 2017;32:23\u201346.","journal-title":"Drug Resist Update"},{"key":"541_CR31","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s10549-006-9328-3","volume":"102","author":"H Kn\u00fcpfer","year":"2007","unstructured":"Kn\u00fcpfer H, Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat. 2007;102:129\u201335.","journal-title":"Breast Cancer Res Treat"},{"key":"541_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.smim.2014.01.008","volume":"26","author":"DT Fisher","year":"2014","unstructured":"Fisher DT, Appenheimer MM, Evans SS. The two faces of IL-6 in the tumor microenvironment. Semin Immunol. 2014;26:38\u201347.","journal-title":"Semin Immunol"},{"key":"541_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2018.09.032","volume":"840","author":"M Cheng","year":"2018","unstructured":"Cheng M, Cai W, Huang W, Chen Y, Wu Z, Luo P, Yan W. Histone deacetylase 6 regulated expression of IL-8 is involved in the doxorubicin (Dox) resistance of osteosarcoma cells via modulating ABCB1 transcription. Eur J Pharmacol. 2018;840:1\u20138.","journal-title":"Eur J Pharmacol"},{"key":"541_CR34","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1158\/0008-5472.CAN-14-2921","volume":"75","author":"S Takeuchi","year":"2015","unstructured":"Takeuchi S, Baghdadi M, Tsuchikawa T, Wada H, Nakamura T, Abe H, Nakanishi S, Usui Y, Higuchi K, Takahashi M, Inoko K, Sato S, Takano H, Shichinohe T, Seino K, Hirano S. Chemotherapy-derived inflammatory responses accelerate the formation of immunosuppressive myeloid cells in the tissue microenvironment of human pancreatic cancer. Cancer Res. 2015;75:2629\u201340.","journal-title":"Cancer Res"},{"key":"541_CR35","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1002\/jcp.26896","volume":"234","author":"E Safarzadeh","year":"2019","unstructured":"Safarzadeh E, Hashemzadeh S, Duijf PHG, Mansoori B, Khaze V, Mohammadi A, Kazemi T, Yousefi M, Asadi M, Mohammadi H, Babaie F, Baradaran B. Circulating myeloid-derived suppressor cells: an independent prognostic factor in patients with breast cancer. J Cell Physiol. 2019;234:3515\u201325.","journal-title":"J Cell Physiol"},{"key":"541_CR36","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s12272-019-01165-6","volume":"42","author":"SM Park","year":"2019","unstructured":"Park SM, Youn JI. Role of myeloid-derived suppressor cells in immune checkpoint inhibitor therapy in cancer. Arch Pharm Res. 2019;42:560\u20136.","journal-title":"Arch Pharm Res."},{"key":"541_CR37","doi-asserted-by":"publisher","first-page":"18217","DOI":"10.1038\/srep18217","volume":"5","author":"M Kawano","year":"2015","unstructured":"Kawano M, Mabuchi S, Matsumoto Y, Sasano T, Takahashi R, Kuroda H, Kozasa K, Hashimoto K, Isobe A, Sawada K, Hamasaki T, Morii E, Kimura T. The significance of G-CSF expression and myeloid-derived suppressor cells in the chemoresistance of uterine cervical cancer. Sci Rep. 2015;5:18217.","journal-title":"Sci Rep."},{"key":"541_CR38","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.blre.2016.04.002","volume":"30","author":"E Malek","year":"2016","unstructured":"Malek E, de Lima M, Letterio JJ, Kim BG, Finke JH, Driscoll JJ, Giralt SA. Myeloid-derived suppressor cells: the green light for myeloma immune escape. Blood Rev. 2016;30:341\u20138.","journal-title":"Blood Rev"},{"key":"541_CR39","first-page":"231","volume":"12","author":"O Bruserud","year":"2001","unstructured":"Bruserud O, Foss B, Petersen H. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L). Eur Cytokine Netw. 2001;12:231\u20138.","journal-title":"Eur Cytokine Netw"},{"key":"541_CR40","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1046\/j.1365-2141.1996.434972.x","volume":"92","author":"G Reisbach","year":"1996","unstructured":"Reisbach G, Kamp T, Welzl G, Geiz C, Abedinpour F, Lodri A, Kaboth W, D\u00f6rmer P, Nerl C. Regulated plasma levels of colony-stimulating factors, interleukin-6 and interleukin-10 in patients with acute leukaemia and non-hodgkin\u2019s lymphoma undergoing cytoreductive chemotherapy. Br J Haematol. 1996;92:907\u201312.","journal-title":"Br J Haematol."},{"key":"541_CR41","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/imm.12508","volume":"146","author":"Y Liu","year":"2015","unstructured":"Liu Y, Zhang L, Zhu X, Wang Y, Liu W, Gong W. Polysaccharide Agaricus blazei Murill stimulates myeloid derived suppressor cell differentiation from M2 to M1 type, which mediates inhibition of tumour immune-evasion via the Toll-like receptor 2 pathway. Immunology. 2015;146:379\u201391.","journal-title":"Immunology"},{"key":"541_CR42","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/CMR.0000000000000352","volume":"27","author":"M Falleni","year":"2017","unstructured":"Falleni M, Savi F, Tosi D, Agape E, Cerri A, Moneghini L, Bulfamante GP. M1 and M2 macrophages\u2019 clinicopathological significance in cutaneous melanoma. Melanoma Res. 2017;27:200\u201310.","journal-title":"Melanoma Res"},{"key":"541_CR43","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2019.01.018","volume":"111","author":"T Yagi","year":"2019","unstructured":"Yagi T, Baba Y, Okadome K, Kiyozumi Y, Hiyoshi Y, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, Watanabe M, Komohara Y, Baba H. Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer. Eur J Cancer. 2019;111:38\u201349.","journal-title":"Eur J Cancer"},{"key":"541_CR44","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1084\/jem.20100587","volume":"207","author":"CA Corzo","year":"2010","unstructured":"Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, Cho HI, Celis E, Quiceno DG, Padhya T, McCaffrey TV, McCaffrey JC, Gabrilovich DI. HIF-1\u03b1 regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med. 2010;207:2439\u201353.","journal-title":"J Exp Med"},{"key":"541_CR45","doi-asserted-by":"publisher","first-page":"7465","DOI":"10.1158\/0008-5472.CAN-10-1439","volume":"70","author":"AL Doedens","year":"2010","unstructured":"Doedens AL, Stockmann C, Rubinstein MP, Liao D, Zhang N, DeNardo DG, Coussens LM, Karin M, Goldrath AW, Johnson RS. Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression. Cancer Res. 2010;70:7465\u201375.","journal-title":"Cancer Res"},{"key":"541_CR46","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1200\/JCO.2013.55.0491","volume":"32","author":"S Adams","year":"2014","unstructured":"Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959\u201366.","journal-title":"J Clin Oncol"},{"key":"541_CR47","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.18.01010","volume":"37","author":"S Loi","year":"2019","unstructured":"Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019;37:559\u201369.","journal-title":"J Clin Oncol"},{"key":"541_CR48","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.pathol.2016.10.010","volume":"49","author":"SJ Luen","year":"2017","unstructured":"Luen SJ, Savas P, Fox SB, Salgado R, Loi S. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. Pathology. 2017;49:141\u201355.","journal-title":"Pathology."}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-019-0541-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12951-019-0541-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-019-0541-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T23:27:14Z","timestamp":1602804434000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-019-0541-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,17]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["541"],"URL":"https:\/\/doi.org\/10.1186\/s12951-019-0541-8","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,17]]},"assertion":[{"value":"22 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"110"}}